Just a few neoantigens may be enough for T cells to control
By A Mystery Man Writer
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
The mechanisms of vaccines and neoantigens in the T cell immune
Cancers, Free Full-Text
Frontiers Progress in Neoantigen Targeted Cancer Immunotherapies
Manufacturing Personalised Cancer Vaccines
Schematic illustration of neoantigen-based cancer immunotherapy
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers - ScienceDirect
Subcellular location of source proteins improves prediction of neoantigens for immunotherapy
When neoantigen expression is low, the T cells won't go
Unleashing the power of DNA: fighting cancer with tailored vaccines
CD4+ CAR T cells kill tumor cells from a distance with IFNγ
